Literature DB >> 2664088

Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse.

R Cantello1, M Aguggia, M Gilli, M Delsedime, I Chiardò Cutin, A Riccio, R Mutani.   

Abstract

The euphoric response to equivalent doses of intravenous methylphenidate (MTP) was assessed in a group of 13 Parkinsonian patients affected by major depression, in a group of 11 nondepressed Parkinsonians, in a group of 14 nonparkinsonian subjects suffering from major depression, and finally in a group of 12 controls with no CNS or psychiatric disease. Subjects of all four groups were matched for age, sex and other main characteristics. Depressed and nondepressed Parkinsonians were also matched for duration and severity of illness, and for the type of antiparkinsonian treatment. The response to MTP was evaluated in the context of a double-blind, placebo-controlled study. Parkinsonian patients with major depression exhibited a significant lack of sensitivity to the euphoriant effects of MTP, in comparison with the other three groups. Euphoria produced by central stimulants has been shown to depend on the activity of a dopamine synapse in humans, which is thought to be situated at the limbic terminals of dopamine neurons located in the ventral tegmental area. Degeneration of this system may have predisposed our Parkinsonian patients to major depression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2664088      PMCID: PMC1032022          DOI: 10.1136/jnnp.52.6.724

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Hedonic capacity: some conjectures.

Authors:  P E Meehl
Journal:  Bull Menninger Clin       Date:  1975-07

3.  Cerebral blood flow in dementia.

Authors:  V C Hachinski; L D Iliff; E Zilhka; G H Du Boulay; V L McAllister; J Marshall; R W Russell; L Symon
Journal:  Arch Neurol       Date:  1975-09

4.  Depressive symptoms in Parkinson patients referred for thalamotomy.

Authors:  J W Warburton
Journal:  J Neurol Neurosurg Psychiatry       Date:  1967-08       Impact factor: 10.154

5.  Endogenomorphic depression. A conceptual and terminological revision.

Authors:  D F Klein
Journal:  Arch Gen Psychiatry       Date:  1974-10

6.  Psychiatric disturbances in Parkinson's disease.

Authors:  G G Celesia; W M Wanamaker
Journal:  Dis Nerv Syst       Date:  1972-09

7.  Blockade of intravenous amphetamine euphoria in man.

Authors:  L E Jönsson; E Anggård; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1971 Nov-Dec       Impact factor: 6.875

8.  A new marker for human cancer cells. 1 The Ca antigen and the Ca1 antibody.

Authors:  F Ashall; M E Bramwell; H Harris
Journal:  Lancet       Date:  1982-07-03       Impact factor: 79.321

9.  Does levodopa alter depression and psychopathology in Parkinsonism patients?

Authors:  G G Marsh; C H Markham
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-12       Impact factor: 10.154

10.  Some psychological factors in Parkinsonism.

Authors:  S Horn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-01       Impact factor: 10.154

View more
  10 in total

Review 1.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

3.  Methylphenidate : a treatment for Parkinson's disease?

Authors:  David Devos; Caroline Moreau; Arnaud Delval; Kathy Dujardin; Luc Defebvre; Regis Bordet
Journal:  CNS Drugs       Date:  2013-01       Impact factor: 5.749

Review 4.  Neuropsychiatric Issues in Parkinson's Disease.

Authors:  Jeffrey W Cooney; Mark Stacy
Journal:  Curr Neurol Neurosci Rep       Date:  2016-05       Impact factor: 5.081

5.  Taste responses in patients with Parkinson's disease.

Authors:  H Sienkiewicz-Jarosz; A Scinska; W Kuran; D Ryglewicz; A Rogowski; E Wrobel; A Korkosz; A Kukwa; W Kostowski; P Bienkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

6.  A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease.

Authors:  S E Starkstein; H S Mayberg; R Leiguarda; T J Preziosi; R G Robinson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

7.  Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease.

Authors:  Connie Veazey; Karon F Cook; Melinda Stanley; Eugene C Lai; Mark E Kunik
Journal:  J Clin Psychol Med Settings       Date:  2009-04-29

Review 8.  Treatment of depression in Parkinson's disease.

Authors:  Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin
Journal:  Curr Psychiatry Rep       Date:  2006-06       Impact factor: 5.285

9.  Antidepressant-like effect of tetrahydroisoquinoline amines in the animal model of depressive disorder induced by repeated administration of a low dose of reserpine: behavioral and neurochemical studies in the rat.

Authors:  Lucyna Antkiewicz-Michaluk; Agnieszka Wąsik; Edyta Możdżeń; Irena Romańska; Jerzy Michaluk
Journal:  Neurotox Res       Date:  2014-01-10       Impact factor: 3.911

Review 10.  Mood, food, and obesity.

Authors:  Minati Singh
Journal:  Front Psychol       Date:  2014-09-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.